SCHEMBL6996573

SCHEMBL6996573

CCOC(=O)c1c(N)sc2cc(C)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.57
ALDH1A1 P00352 9/20 0.57
HPGD P15428 6/20 0.57
GAA P10253 4/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALOX15 P16050 4/20 0.55
TSHR P16473 2/20 0.55
USP2 O75604 1/20 0.54
NPSR1 Q6W5P4 2/20 0.53
FHIT P49789 1/20 0.53
CISD2 Q8N5K1 1/20 0.52
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HSD17B10 Q99714 2/20 0.49
MAPK1 P28482 2/20 0.49
GRM6 O15303 5/20 0.49
TDP1 Q9NUW8 1/20 0.49
MPI P34949 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24683238 0.87 MAPT (0.57) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL14539618 0.86 MAPT (0.54) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL2308619 0.86 MAPT (0.60) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL6992051 0.86 GRM6 (0.57) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL8203054 0.84 MAPT (0.52) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL7695574 0.83 MAPT (0.42) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL2307828 0.82 MAPT (0.60) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL5166243 0.82 GRM6 (0.62) MAPTALDH1A1HPGDGAASMN1; SMN2
SCHEMBL28077673 0.80 MCL1 (0.54) MAPTALDH1A1GAASMN1; SMN2CISD2
SCHEMBL19140015 0.78 ALDH1A1 (0.48) MAPTALDH1A1HPGDGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885ALDH1A1 366/4885HPGD 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.